UK Markets closed

Vectura Group plc (VEC.L)


LSE - LSE Delayed price. Currency in GBp
Add to watchlist
114.40+0.90 (+0.79%)
At close: 4:35PM BST
People also watch
VER.LOXB.LBTG.LHIK.LDPH.L
Full screen
Previous close113.50
Open112.40
Bid108.00 x 382500
Ask0.00 x 252100
Day's range111.70 - 114.90
52-week range109.50 - 166.97
Volume1,098,039
Avg. volume2,185,304
Market cap775.6M
Beta0.22
PE ratio (TTM)-16.34
EPS (TTM)-7
Earnings dateN/A
Dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target est181.88
  • Fool.co.uk27 days ago

    These growth stocks are trading at major discounts

    Are these two companies cheap enough to merit purchase right now?

  • Reuters - UK Focus2 months ago

    GSK escapes Advair hit for now as second generic bid fails

    GlaxoSmithKline (Other OTC: GLAXF - news) is likely to escape generic competition to its blockbuster lung drug Advair in the United States this year, after a second application for a cut-price equivalent form of the medicine was turned down by U.S. regulators. Hikma Pharmaceuticals (Frankfurt: A0HG69 - news) said on Thursday the Food and Drug Administration (FDA) had decided not to approve its version of the inhaled treatment for asthma and chronic lung disease at this time, due to "major" issues with the application. Hikma and its partner Vectura are in a race with Mylan to launch the first U.S. generic copy of Advair that can be substituted for the original product in pharmacies.

  • Reuters - UK Focus2 months ago

    BUZZ-Hikma: bottom of STOXX as generic Advair faces US delay, 2017 approval unlikely

    ** Drugmaker Hikma down 8 pct, bottom of Stoxx 600 , with its partner Vectura -9% ** Hikma says US regulators have decided not to approve its generic copy of GlaxoSmithKline's blockbuster lung drug Advair ...